JP2015533176A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015533176A5 JP2015533176A5 JP2015537018A JP2015537018A JP2015533176A5 JP 2015533176 A5 JP2015533176 A5 JP 2015533176A5 JP 2015537018 A JP2015537018 A JP 2015537018A JP 2015537018 A JP2015537018 A JP 2015537018A JP 2015533176 A5 JP2015533176 A5 JP 2015533176A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- ezh2
- pharmaceutically acceptable
- compound according
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261714140P | 2012-10-15 | 2012-10-15 | |
| US201261714145P | 2012-10-15 | 2012-10-15 | |
| US61/714,145 | 2012-10-15 | ||
| US61/714,140 | 2012-10-15 | ||
| US201361780703P | 2013-03-13 | 2013-03-13 | |
| US61/780,703 | 2013-03-13 | ||
| US201361786277P | 2013-03-14 | 2013-03-14 | |
| US61/786,277 | 2013-03-14 | ||
| PCT/US2013/065126 WO2014062732A1 (en) | 2012-10-15 | 2013-10-15 | Substituted benzene compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018028891A Division JP2018087238A (ja) | 2012-10-15 | 2018-02-21 | 置換ベンゼン化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015533176A JP2015533176A (ja) | 2015-11-19 |
| JP2015533176A5 true JP2015533176A5 (enExample) | 2016-12-01 |
| JP6461802B2 JP6461802B2 (ja) | 2019-01-30 |
Family
ID=50475881
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015537018A Expired - Fee Related JP6461802B2 (ja) | 2012-10-15 | 2013-10-15 | 置換ベンゼン化合物 |
| JP2015537019A Expired - Fee Related JP6461803B2 (ja) | 2012-10-15 | 2013-10-15 | 置換ベンゼン化合物 |
| JP2018028891A Withdrawn JP2018087238A (ja) | 2012-10-15 | 2018-02-21 | 置換ベンゼン化合物 |
| JP2018028907A Active JP6559275B2 (ja) | 2012-10-15 | 2018-02-21 | 置換ベンゼン化合物 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015537019A Expired - Fee Related JP6461803B2 (ja) | 2012-10-15 | 2013-10-15 | 置換ベンゼン化合物 |
| JP2018028891A Withdrawn JP2018087238A (ja) | 2012-10-15 | 2018-02-21 | 置換ベンゼン化合物 |
| JP2018028907A Active JP6559275B2 (ja) | 2012-10-15 | 2018-02-21 | 置換ベンゼン化合物 |
Country Status (23)
| Country | Link |
|---|---|
| US (8) | US10092572B2 (enExample) |
| EP (4) | EP2906537B1 (enExample) |
| JP (4) | JP6461802B2 (enExample) |
| KR (2) | KR102057365B1 (enExample) |
| CN (3) | CN105102432B (enExample) |
| AR (1) | AR093244A1 (enExample) |
| AU (2) | AU2013331381B2 (enExample) |
| BR (2) | BR112015008487B1 (enExample) |
| CA (2) | CA2888021A1 (enExample) |
| CL (2) | CL2015000944A1 (enExample) |
| HK (2) | HK1213552A1 (enExample) |
| IL (4) | IL238135B (enExample) |
| MX (2) | MX2015004721A (enExample) |
| MY (1) | MY180311A (enExample) |
| NZ (2) | NZ706739A (enExample) |
| PE (2) | PE20150887A1 (enExample) |
| PH (2) | PH12015500800B1 (enExample) |
| RU (2) | RU2662436C2 (enExample) |
| SG (3) | SG11201502820YA (enExample) |
| TW (2) | TWI651303B (enExample) |
| UA (2) | UA115074C2 (enExample) |
| WO (2) | WO2014062733A2 (enExample) |
| ZA (2) | ZA201502526B (enExample) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130102477A1 (en) | 2010-06-23 | 2013-04-25 | Ryan D. Morin | Biomarkers for non-hodgkin lymphomas and uses thereof |
| US9175331B2 (en) * | 2010-09-10 | 2015-11-03 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
| TW201733984A (zh) | 2011-04-13 | 2017-10-01 | 雅酶股份有限公司 | 經取代之苯化合物 |
| JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| EP2780013A4 (en) | 2011-11-18 | 2015-07-01 | Constellation Pharmaceuticals Inc | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF |
| NZ628762A (en) | 2012-02-10 | 2016-07-29 | Constellation Pharmaceuticals Inc | Modulators of methyl modifying enzymes, compositions and uses thereof |
| RU2018145311A (ru) | 2012-10-15 | 2019-02-18 | Эпизайм, Инк. | Способы лечения рака |
| JP6461802B2 (ja) | 2012-10-15 | 2019-01-30 | エピザイム，インコーポレイティド | 置換ベンゼン化合物 |
| BR112015014090A2 (pt) | 2012-12-13 | 2017-07-11 | Glaxosmithkline Llc | intensificador de inibidores de zeste homólogo 2 |
| CA2894216A1 (en) * | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | 1,4-pyridone compounds |
| EP2935264B1 (en) | 2012-12-21 | 2017-10-18 | Epizyme, Inc. | 1,4-pyridone bicyclic heteroaryl compounds |
| JP6218860B2 (ja) | 2013-03-14 | 2017-10-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | カテプシンｃの置換２−アザ−ビシクロ［２．２．１］ヘプタン−３−カルボン酸（ベンジル−シアノ−メチル）−アミド阻害剤 |
| TWI627174B (zh) | 2013-03-14 | 2018-06-21 | 比利時商健生藥品公司 | Ｐ２ｘ７調控劑 |
| JP6294953B2 (ja) | 2013-03-14 | 2018-03-14 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｐ２ｘ７調節物質 |
| US9040534B2 (en) | 2013-03-14 | 2015-05-26 | Janssen Pharmaceutica Nv | [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators |
| TWI599567B (zh) | 2013-03-14 | 2017-09-21 | 健生藥品公司 | Ｐ２ｘ７調節劑 |
| EP2970305B1 (en) | 2013-03-15 | 2017-02-22 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| CN105473580A (zh) | 2013-07-10 | 2016-04-06 | 葛兰素史密斯克莱知识产权（第2号）有限公司 | Zeste同源物增强子2抑制剂 |
| EP3022184B1 (en) | 2013-07-19 | 2017-09-27 | Epizyme, Inc. | Substituted benzene compounds |
| EP3022195A2 (en) | 2013-07-19 | 2016-05-25 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| EP3033334A1 (en) | 2013-08-15 | 2016-06-22 | Constellation Pharmaceuticals, Inc. | Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof |
| HUE063984T2 (hu) | 2013-10-16 | 2024-02-28 | Epizyme Inc | Hidroklorid só forma az EZH2 gátlásához |
| AU2014360078A1 (en) | 2013-12-06 | 2016-06-09 | Epizyme, Inc. | Combination therapy for treating cancer |
| PT3157527T (pt) | 2014-06-17 | 2023-06-30 | Eisai R&D Man Co Ltd | Inibidores de ezh2 para tratamento de linfoma |
| AU2015315693B2 (en) | 2014-09-12 | 2020-01-16 | Janssen Pharmaceutica Nv | P2X7 modulating n-acyl-triazolopyrazines |
| EA034015B1 (ru) | 2014-09-12 | 2019-12-19 | Янссен Фармацевтика Нв | Модуляторы р2х7 |
| AU2015314355B2 (en) | 2014-09-12 | 2019-06-20 | Boehringer Ingelheim International Gmbh | Spirocyclic inhibitors of Cathepsin C |
| SG10201903356XA (en) * | 2014-10-16 | 2019-05-30 | Epizyme Inc | Method for treating cancer |
| SG11201703806XA (en) | 2014-11-17 | 2017-06-29 | Epizyme Inc | Method for treating cancer |
| WO2016101956A2 (en) | 2014-12-23 | 2016-06-30 | University Of Copenhagen | Treatment of cancer by inhibiting ezh2 activity |
| EA201792304A1 (ru) | 2015-04-20 | 2018-03-30 | Эпизайм, Инк. | Комбинированная терапия для лечения рака |
| JP6890097B2 (ja) | 2015-06-10 | 2021-06-18 | エピザイム，インコーポレイティド | リンパ腫を処置するためのｅｚｈ２阻害剤 |
| CN108025191A (zh) | 2015-08-24 | 2018-05-11 | Epizyme股份有限公司 | 治疗癌症的方法 |
| TW201718598A (zh) | 2015-08-27 | 2017-06-01 | 美國禮來大藥廠 | Ｅｚｈ２抑制劑 |
| US10577350B2 (en) | 2015-08-28 | 2020-03-03 | Constellation Pharmaceuticals, Inc. | Crystalline forms of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide |
| AU2017211331A1 (en) | 2016-01-29 | 2018-06-07 | Epizyme, Inc. | Combination therapy for treating cancer |
| CA3018270A1 (en) * | 2016-04-22 | 2017-10-26 | Dana-Farber Cancer Institute, Inc. | Ezh2 inhibitors and uses thereof |
| AU2017273726B2 (en) | 2016-06-01 | 2023-10-19 | Epizyme, Inc. | Use of EZH2 inhibitors for treating cancer |
| US11147819B2 (en) | 2016-06-17 | 2021-10-19 | Epizyme, Inc. | EZH2 inhibitors for treating cancer |
| WO2018075598A1 (en) | 2016-10-19 | 2018-04-26 | Constellation Pharmaceuticals, Inc. | Synthesis of inhibitors of ezh2 |
| CN108699002B (zh) * | 2016-11-11 | 2021-11-09 | 上海海雁医药科技有限公司 | 1,5,7-三取代的异喹啉衍生物、其制法与医药上的用途 |
| US10266542B2 (en) | 2017-03-15 | 2019-04-23 | Mirati Therapeutics, Inc. | EZH2 inhibitors |
| US11642346B2 (en) | 2017-03-31 | 2023-05-09 | Epizyme, Inc. | Combination therapy for treating cancer |
| AU2018275123A1 (en) | 2017-06-02 | 2020-01-30 | Epizyme, Inc. | Use of EZH2 inhibitors for treating cancer |
| US11452727B2 (en) | 2017-09-05 | 2022-09-27 | Epizyme, Inc. | Combination therapy for treating cancer |
| WO2019152419A1 (en) | 2018-01-31 | 2019-08-08 | Mirati Therapeutics, Inc | Prc2 inhibitors |
| EP3823671B1 (en) | 2018-07-09 | 2024-02-07 | Fondation Asile Des Aveugles | Inhibition of prc2 subunits to treat eye disorders |
| KR20210069079A (ko) | 2018-09-28 | 2021-06-10 | 얀센 파마슈티카 엔.브이. | 모노아실글리세롤 리파아제 조절제 |
| MA53721A (fr) | 2018-09-28 | 2021-09-15 | Janssen Pharmaceutica Nv | Modulateurs de la monoacylglycérol lipase |
| EP3959214A1 (en) | 2019-04-22 | 2022-03-02 | Mirati Therapeutics, Inc. | Naphthyridine derivatives as prc2 inhibitors |
| CA3142711A1 (en) | 2019-06-05 | 2020-12-10 | Mirati Therapeutics, Inc. | Imidazo[1,2-c]pyrimidine derivatives as prc2 inhibitors for treating cancer |
| CN114555112A (zh) | 2019-08-22 | 2022-05-27 | 朱诺治疗学股份有限公司 | T细胞疗法和zeste增强子同源物2(ezh2)抑制剂的组合疗法及相关方法 |
| WO2021064569A1 (en) | 2019-09-30 | 2021-04-08 | Janssen Pharmaceutica Nv | Radiolabelled mgl pet ligands |
| CN111303133A (zh) * | 2020-03-25 | 2020-06-19 | 清华大学 | 降解ezh2蛋白的小分子化合物 |
| BR112022019077A2 (pt) | 2020-03-26 | 2022-12-27 | Janssen Pharmaceutica Nv | Moduladores da monoacilglicerol lipase |
| CA3230149A1 (en) * | 2021-08-30 | 2023-03-09 | Xiaojing Zhang | Use of ezh2 inhibitor in preparation of drug for treating t-cell lymphoma |
Family Cites Families (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| JPH0733729A (ja) | 1993-07-26 | 1995-02-03 | Kirin Brewery Co Ltd | Ｎ−シアノ−ｎ′−置換−アリールカルボキシイミダミド化合物の製造法 |
| KR100189863B1 (ko) | 1993-12-27 | 1999-06-01 | 나이또 하루오 | 안트라닐산 유도체 |
| DE19516776A1 (de) | 1995-05-10 | 1996-11-14 | Boehringer Ingelheim Int | Chromatin-Regulatorgene |
| US5741819A (en) | 1995-06-07 | 1998-04-21 | 3-Dimensional Pharmaceuticals, Inc. | Arylsulfonylaminobenzene derivatives and the use thereof as factor Xa inhibitors |
| US5763263A (en) | 1995-11-27 | 1998-06-09 | Dehlinger; Peter J. | Method and apparatus for producing position addressable combinatorial libraries |
| JP3906935B2 (ja) | 1995-12-18 | 2007-04-18 | 杏林製薬株式会社 | Ｎ−置換ジオキソチアゾリジルベンズアミド誘導体及びその製造法 |
| BR9914207A (pt) | 1998-09-30 | 2001-07-03 | Procter & Gamble | Ceto-amidas 2-substituìdas |
| UA71587C2 (uk) | 1998-11-10 | 2004-12-15 | Шерінг Акцієнгезелльшафт | Аміди антранілової кислоти та їхнє застосування як лікарських засобів |
| US6710058B2 (en) | 2000-11-06 | 2004-03-23 | Bristol-Myers Squibb Pharma Company | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors |
| WO2002053543A1 (en) | 2000-12-28 | 2002-07-11 | Shionogi & Co., Ltd. | Pyridone derivative having affinity for cannabinoid 2-type receptor |
| EP1363702A4 (en) | 2001-01-30 | 2007-08-22 | Cytopia Pty Ltd | PROCESS FOR INHIBITING KINASES |
| US7700293B2 (en) | 2001-08-02 | 2010-04-20 | The Regents Of The University Of Michigan | Expression profile of prostate cancer |
| AU2002351412B2 (en) | 2001-12-21 | 2010-05-20 | Exelixis Patent Company Llc | Modulators of LXR |
| ATE447971T1 (de) | 2002-02-19 | 2009-11-15 | Shionogi & Co | Antipruriginosa |
| TW200306155A (en) | 2002-03-19 | 2003-11-16 | Du Pont | Benzamides and advantageous compositions thereof for use as fungicides |
| BRPI0317740B8 (pt) | 2002-12-27 | 2021-05-25 | Sucampo Ag | uso do composto 13,14-diidro-15-ceto-16,16-diflúorprostaglandina e1 |
| US7405295B2 (en) | 2003-06-04 | 2008-07-29 | Cgi Pharmaceuticals, Inc. | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds |
| US7442685B2 (en) | 2003-06-13 | 2008-10-28 | The University Of North Carolina At Chapel Hill | DOT1 histone methyltransferases as a target for identifying therapeutic agents for leukemia |
| WO2004112719A2 (en) | 2003-06-19 | 2004-12-29 | Smithkline Beecham Corporation | Chemical compounds |
| BR122016015715B8 (pt) | 2003-07-23 | 2021-05-25 | Bayer Healthcare Llc | composições farmacêuticas de metilamida de ácido 4[4-[3-(4-cloro-3-trifluorometilfenil)-ureido]-3-fluorofenóxi)-piridina-2-carboxílico |
| EP2201947A3 (en) | 2003-08-26 | 2010-08-11 | Merck HDAC Research, LLC | Use of SAHA for treating mesothelioma |
| US20050059682A1 (en) | 2003-09-12 | 2005-03-17 | Supergen, Inc., A Delaware Corporation | Compositions and methods for treatment of cancer |
| DE602005021770D1 (de) * | 2004-03-11 | 2010-07-22 | Actelion Pharmaceuticals Ltd | Indol-1-yl-essigsäurederivate |
| CN1286973C (zh) | 2004-04-12 | 2006-11-29 | 上海第二医科大学附属瑞金医院 | 一种组蛋白甲基转移酶及其制备方法 |
| US7563589B2 (en) | 2004-06-01 | 2009-07-21 | The University Of North Carolina At Chapel Hill | Reconstituted histone methyltransferase complex and methods of identifying modulators thereof |
| JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
| EP1891434B1 (en) | 2005-06-02 | 2011-01-05 | The University of North Carolina at Chapel Hill | Purification, characterization and reconstitution of a ubiquitin e3 ligase |
| FR2889526B1 (fr) | 2005-08-04 | 2012-02-17 | Aventis Pharma Sa | 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation |
| BRPI0618417A2 (pt) | 2005-10-19 | 2012-07-31 | Gruenenthal Chemie | novos ligandos de receptores de vanilàide e seu uso para produzir medicamentos |
| AU2006306541B2 (en) | 2005-10-21 | 2011-07-14 | Merck Sharp & Dohme Corp. | Potassium channel inhibitors |
| AU2006308957B2 (en) | 2005-10-28 | 2012-04-12 | The University Of North Carolina At Chapel Hill | Protein demethylases comprising a JmjC domain |
| WO2007072225A2 (en) | 2005-12-01 | 2007-06-28 | Medical Prognosis Institute | Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy |
| KR20080080173A (ko) | 2005-12-14 | 2008-09-02 | 브리스톨-마이어스 스큅 컴퍼니 | 세린 프로테아제 억제제로서 유용한 6-원 헤테로사이클 |
| AU2006336552B2 (en) | 2006-01-20 | 2012-12-20 | The University Of North Carolina At Chapel Hill | Diagnostic and therapeutic targets for leukemia |
| US20100016379A1 (en) | 2006-05-15 | 2010-01-21 | Irm Llc | Terephthalamate Compounds and Compositions, and Their Use as HIV Integrase Inhibitors |
| EP2040711A2 (en) | 2006-05-18 | 2009-04-01 | Amphora Discovery Corporation | 2-oxo-1,2-dihydroquinoline derivatives, compositions, and uses thereof as antiproliferative agents |
| US8022246B2 (en) | 2006-10-10 | 2011-09-20 | The Burnham Institute For Medical Research | Neuroprotective compositions and methods |
| WO2008103277A2 (en) | 2007-02-16 | 2008-08-28 | Amgen Inc. | Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors |
| WO2008104077A1 (en) | 2007-02-28 | 2008-09-04 | Methylgene Inc. | Small molecule inhibitors of protein arginine methyltransferases (prmts) |
| WO2008109534A1 (en) | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting ezh2 gene expression and uses thereof |
| WO2008113006A1 (en) | 2007-03-14 | 2008-09-18 | Xenon Pharmaceuticals Inc. | Methods of using quinolinone compounds in treating sodium channel-mediated diseases or conditions |
| DE102007017884A1 (de) | 2007-04-13 | 2008-10-16 | Grünethal GmbH | Neue Vanilloid-Rezeptor Liganden und ihre Verwendung zur Herstellung von Arzneimitteln |
| US20090012031A1 (en) | 2007-07-03 | 2009-01-08 | The Regents Of The University Of Michigan | EZH2 Cancer Markers |
| JP5364875B2 (ja) | 2007-07-16 | 2013-12-11 | アッヴィ・インコーポレイテッド | タンパク質キナーゼ阻害薬としてのインダゾール類、ベンゾイソオキサゾール類およびベンゾイソチアゾール類 |
| JP2011502148A (ja) | 2007-10-31 | 2011-01-20 | メルク・シャープ・エンド・ドーム・コーポレイション | 疼痛の治療用としてのｐ２ｘ３受容体アンタゴニスト |
| UA105763C2 (uk) | 2007-12-19 | 2014-06-25 | Кансер Рісерч Текнолоджі Лімітед | 8-ЗАМІЩЕНІ ПІРИДО[2,3-b]ПІРАЗИНИ ТА ЇХ ЗАСТОСУВАННЯ |
| JP5693239B2 (ja) | 2008-01-23 | 2015-04-01 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ４−ピリジノン化合物および癌についてのその使用 |
| WO2009124137A2 (en) | 2008-04-01 | 2009-10-08 | Mount Sinai School Of Medicine Of New York University | Method of suppressing gene transcription through histone lysine methylation |
| US20100113415A1 (en) | 2008-05-29 | 2010-05-06 | Rajapakse Hemaka A | Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer |
| UY31982A (es) | 2008-07-16 | 2010-02-26 | Boehringer Ingelheim Int | Derivados de 1,2-dihidropiridin-3-carboxamidas n-sustituidas |
| EP2323660A2 (en) | 2008-08-08 | 2011-05-25 | New York Blood Center | Small molecule inhibitors of retroviral assembly and maturation |
| FR2934995B1 (fr) | 2008-08-14 | 2010-08-27 | Sanofi Aventis | Composes d'azetidines polysubstitues, leur preparation et leur application en therapeutique |
| BRPI0924844A2 (pt) | 2009-03-24 | 2016-01-26 | Sanofi Sa | derivados de azacarbolinas 9h-pirrol[2,3-b:5,4-c']dipiridina, sua preparação e sua utilização terapêutica. |
| EP2411007A4 (en) | 2009-03-27 | 2012-12-05 | Uab Research Foundation | MODULATION OF IRES-MEDIATED TRANSLATION |
| WO2011011366A2 (en) | 2009-07-20 | 2011-01-27 | Constellation Pharmaceuticals | Agents for stimulating activity of methyl modifying enzymes and methods of use thereof |
| WO2011082044A1 (en) | 2009-12-30 | 2011-07-07 | Avon Products, Inc. | Topical lightening composition and uses thereof |
| ES2528269T3 (es) | 2010-05-07 | 2015-02-06 | Glaxosmithkline Llc | Azaindazoles |
| MX2012012966A (es) * | 2010-05-07 | 2013-01-22 | Glaxosmithkline Llc | Indoles. |
| JP5864546B2 (ja) | 2010-05-07 | 2016-02-17 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ | インダゾール |
| US20130102477A1 (en) | 2010-06-23 | 2013-04-25 | Ryan D. Morin | Biomarkers for non-hodgkin lymphomas and uses thereof |
| US9175331B2 (en) | 2010-09-10 | 2015-11-03 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
| AU2011298987B2 (en) | 2010-09-10 | 2017-09-28 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
| US20130310379A1 (en) | 2010-11-19 | 2013-11-21 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| JP5908493B2 (ja) | 2010-12-01 | 2016-04-26 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ | インドール |
| BR112013013668A2 (pt) | 2010-12-03 | 2016-09-06 | Epizyme Inc | moduladores 7-deazapurina de histona metiltransferase, e métodos de uso dos mesmos |
| US8791782B2 (en) * | 2011-01-28 | 2014-07-29 | Uses, Inc. | AC power conditioning circuit |
| EP3323820B1 (en) | 2011-02-28 | 2023-05-10 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| TW201733984A (zh) * | 2011-04-13 | 2017-10-01 | 雅酶股份有限公司 | 經取代之苯化合物 |
| JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| JP2014534178A (ja) | 2011-09-30 | 2014-12-18 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ | 癌の処置方法 |
| AU2013232229B2 (en) * | 2012-03-12 | 2017-11-23 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
| SG10201608579UA (en) | 2012-04-13 | 2016-12-29 | Epizyme Inc | Combination therapy for treating cancer |
| LT2836491T (lt) * | 2012-04-13 | 2017-03-27 | Epizyme, Inc. | Žmogaus histono metiltransferazės ezh2 slopiklio druskos forma |
| US9562041B2 (en) | 2012-05-16 | 2017-02-07 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
| RU2018145311A (ru) * | 2012-10-15 | 2019-02-18 | Эпизайм, Инк. | Способы лечения рака |
| JP6461802B2 (ja) | 2012-10-15 | 2019-01-30 | エピザイム，インコーポレイティド | 置換ベンゼン化合物 |
-
2013
- 2013-10-15 JP JP2015537018A patent/JP6461802B2/ja not_active Expired - Fee Related
- 2013-10-15 SG SG11201502820YA patent/SG11201502820YA/en unknown
- 2013-10-15 AU AU2013331381A patent/AU2013331381B2/en not_active Ceased
- 2013-10-15 BR BR112015008487-7A patent/BR112015008487B1/pt not_active IP Right Cessation
- 2013-10-15 HK HK16101447.9A patent/HK1213552A1/zh unknown
- 2013-10-15 CN CN201380065683.2A patent/CN105102432B/zh active Active
- 2013-10-15 AR ARP130103745A patent/AR093244A1/es active IP Right Grant
- 2013-10-15 MX MX2015004721A patent/MX2015004721A/es active IP Right Grant
- 2013-10-15 RU RU2015118135A patent/RU2662436C2/ru active
- 2013-10-15 US US14/435,704 patent/US10092572B2/en active Active
- 2013-10-15 RU RU2015118145A patent/RU2658919C2/ru active
- 2013-10-15 JP JP2015537019A patent/JP6461803B2/ja not_active Expired - Fee Related
- 2013-10-15 WO PCT/US2013/065127 patent/WO2014062733A2/en not_active Ceased
- 2013-10-15 WO PCT/US2013/065126 patent/WO2014062732A1/en not_active Ceased
- 2013-10-15 CN CN201380065677.7A patent/CN105102431B/zh active Active
- 2013-10-15 PE PE2015000489A patent/PE20150887A1/es active IP Right Grant
- 2013-10-15 EP EP13846696.6A patent/EP2906537B1/en active Active
- 2013-10-15 HK HK16101355.9A patent/HK1213264A1/zh unknown
- 2013-10-15 UA UAA201504700A patent/UA115074C2/uk unknown
- 2013-10-15 SG SG11201502803VA patent/SG11201502803VA/en unknown
- 2013-10-15 MX MX2015004722A patent/MX353929B/es active IP Right Grant
- 2013-10-15 MY MYPI2015000966A patent/MY180311A/en unknown
- 2013-10-15 KR KR1020157012670A patent/KR102057365B1/ko not_active Expired - Fee Related
- 2013-10-15 EP EP20161557.2A patent/EP3725314A1/en not_active Withdrawn
- 2013-10-15 CA CA2888021A patent/CA2888021A1/en not_active Abandoned
- 2013-10-15 NZ NZ706739A patent/NZ706739A/en not_active IP Right Cessation
- 2013-10-15 NZ NZ706738A patent/NZ706738A/en not_active IP Right Cessation
- 2013-10-15 TW TW106111749A patent/TWI651303B/zh not_active IP Right Cessation
- 2013-10-15 EP EP19188699.3A patent/EP3628662A1/en not_active Withdrawn
- 2013-10-15 KR KR1020157012673A patent/KR102057366B1/ko not_active Expired - Fee Related
- 2013-10-15 EP EP13847763.3A patent/EP2906538A4/en not_active Withdrawn
- 2013-10-15 AU AU2013331380A patent/AU2013331380B2/en not_active Ceased
- 2013-10-15 CA CA2887562A patent/CA2887562C/en active Active
- 2013-10-15 PE PE2015000488A patent/PE20150886A1/es active IP Right Grant
- 2013-10-15 BR BR112015008480A patent/BR112015008480A2/pt not_active IP Right Cessation
- 2013-10-15 US US14/054,695 patent/US9006242B2/en active Active
- 2013-10-15 SG SG10201705989YA patent/SG10201705989YA/en unknown
- 2013-10-15 TW TW102137117A patent/TWI588131B/zh active
- 2013-10-15 UA UAA201504699A patent/UA119136C2/uk unknown
- 2013-10-15 CN CN201811510752.7A patent/CN110041250A/zh active Pending
-
2015
- 2015-03-05 US US14/639,878 patent/US9089575B2/en active Active
- 2015-04-02 IL IL238135A patent/IL238135B/en active IP Right Grant
- 2015-04-10 PH PH12015500800A patent/PH12015500800B1/en unknown
- 2015-04-12 IL IL238197A patent/IL238197A0/en active IP Right Grant
- 2015-04-15 CL CL2015000944A patent/CL2015000944A1/es unknown
- 2015-04-15 ZA ZA2015/02526A patent/ZA201502526B/en unknown
- 2015-04-15 CL CL2015000942A patent/CL2015000942A1/es unknown
- 2015-04-15 PH PH12015500825A patent/PH12015500825A1/en unknown
- 2015-04-16 ZA ZA2015/02560A patent/ZA201502560B/en unknown
- 2015-06-17 US US14/742,466 patent/US9532992B2/en active Active
-
2016
- 2016-11-22 US US15/359,538 patent/US10098888B2/en active Active
-
2018
- 2018-02-21 JP JP2018028891A patent/JP2018087238A/ja not_active Withdrawn
- 2018-02-21 JP JP2018028907A patent/JP6559275B2/ja active Active
- 2018-09-04 US US16/120,702 patent/US20190060322A1/en not_active Abandoned
- 2018-09-26 IL IL261964A patent/IL261964B/en active IP Right Grant
-
2019
- 2019-03-18 IL IL265437A patent/IL265437A/en unknown
-
2020
- 2020-07-09 US US16/924,962 patent/US11642348B2/en active Active
-
2023
- 2023-03-23 US US18/188,700 patent/US20240165121A1/en not_active Abandoned